belzutifan (Welireg) plus lenvatinib (Lenvima): FDA status

Approved Approved Sep 24, 2026. Indication: advanced clear cell renal cell carcinoma previously treated. Company: Merck.

Regulatory history

All products in the FDA Tracker

Loading today's edition…